title: Cytotoxic Activity of Bioactive Compound 1, 2- Benzene Dicarboxylic Acid, Mono 2- Ethylhexyl Ester Extracted from a Marine Derived Streptomyces sp. VITSJK8.
abstract: Marine Streptomyces are prolific producers of majority of bioactive secondary metabolites which are used in pharmaceutical industry as effective drugs against life threatening diseases. The cytotoxic activity of the pure compound 1, 2- benzene dicarboxylic acid, mono 2- ethylhexyl ester (DMEHE) from marine derived actinomycete Streptomyces sp. VITSJK8 was investigated against mouse embryonic fibroblast (NIH 3T3) and human keratinocyte (HaCaT) normal cell lines, human hepatocellular liver carcinoma (HepG 2) and human breast adenocarcinoma (MCF-7) cell lines by using MTT assay. The compound DMEHE exhibited IC 50 values of 42, 100, 250 and 500 µg/ ml against HepG2, MCF-7, HaCaT and NIH 3T3 cell lines, respectively. The effect of DMEHE on the growth of cancer cell lines was expressed as the % of viability. Cell viability was recorded as 67.7%, 78.14%, 82.23% and 96. 11% in HepG2, MCF-7, HaCaT and NIH 3T3 cells, respectively. The results of the study conclude that the bioactive compound isolated from the potential isolate Streptomyces sp. VITSJK8 exhibited cytotoxic activity against HepG2 and MCF- 7 cancer cell lines and low toxicity against normal HaCaT and NIH 3T3 cell lines.
authors: School of Biosciences and Technology, VIT University, Tamilnadu, India.
authors: Kannabiran
authors: K
authors: Krishnan
authors: School of Biosciences and Technology, VIT University, Tamilnadu, India.
authors: Abirami
authors: A
authors: Mani
authors: School of Biosciences and Technology, VIT University, Tamilnadu, India.
authors: Subashini
authors: S
authors: Jasmine
keywords: 1; 2- benzene dicarboxylic acid; MTT assay; Streptomyces sp. VITSJK8; cytotoxicity; mono 2- ethylhexyl ester
references: Asian Pac J Cancer Prev. 2013;14(3):1829-32
references: 23679282
references: J Antibiot (Tokyo). 2005 Jan;58(1):1-26
references: 15813176
references: PLoS One. 2013 Oct 01;8(10):e75994
references: 24098415
references: J Antibiot (Tokyo). 1995 Aug;48(8):768-72
references: 7592019
references: Nat Rev Cancer. 2005 Jan;5(1):65-72
references: 15630416
references: Bioorg Med Chem Lett. 2011 Apr 15;21(8):2313-5
references: 21411320
references: Int J Mol Cell Med. 2012 Fall;1(4):197-202
references: 24551778
references: Springerplus. 2013 Mar 09;2(1):93
references: 23741637
references: Microbiol Res. 2014 Apr;169(4):262-78
references: 23958059
references: Mar Drugs. 2009 Jun 11;7(2):210-48
references: 19597582
references: Saudi J Biol Sci. 2012 Jan;19(1):81-6
references: 23961165
references: J Antibiot (Tokyo). 1993 Oct;46(10):1530-5
references: 8244880
references: Int J Equity Health. 2005 Jan 14;4(1):2
references: 15651987
references: Microbiol Res. 2012 Dec 20;167(10):571-80
references: 22796410
references: World J Microbiol Biotechnol. 2013 Jul;29(7):1271-8
references: 23420111
references: Evid Based Complement Alternat Med. 2013;2013:257108
references: 23762112
references: Mar Drugs. 2014 Jun 10;12(6):3516-59
references: 24918453
references: Cell Biol Int. 2006 Nov;30(11):924-32
references: 16895761